Skip to content

Misoprostol for Management of Women With an Incomplete Miscarriage

Comparative Study Between Two Doses of Misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment: A Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05088720
Enrollment
200
Registered
2021-10-22
Start date
2021-11-01
Completion date
2023-03-31
Last updated
2021-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Miscarriage

Brief summary

Miscarriage is defined as the spontaneous loss of a pregnancy before 24 weeks gestation, that is, before fetal viability. The clinical signs of miscarriage are usually vaginal bleeding associated with abdominal pain and cramping. The miscarriage is named 'complete' or 'incomplete' according to whether or not tissues are retained in the uterus. If a woman has minimal bleeding but her cervix is closed, this is known as a 'threatened miscarriage. However; if the pregnancy is still inside the uterus but the cervix is open, this is described as an 'inevitable miscarriage', which it will not usually be possible to save the fetus.

Detailed description

the aim of the study is to evaluate 2 doses with misoprostol in Women With Incomplete First-trimester Miscarriage After Misoprostol Treatment

Interventions

DRUGmisoprostol 800 µg

received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually

DRUGmisoprostol 400 µg

received misoprostol 400 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose sublingually

Sponsors

Aswan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

a double-blind placebo-controlled randomized trial

Intervention model description

a double-blind placebo-controlled randomized trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Women with confirmed incomplete induced miscarriage, less than 12 weeks' gestation. * No known allergy to misoprostol. * Women who will be hemodynamically stable. * Good access to emergency facilities

Exclusion criteria

* Women with signs of severe infection ( fever \> 38°) * Women with severe vaginal bleeding * Women are known to have allergies to prostaglandins * Severe abdominal pain requiring immediate intervention

Design outcomes

Primary

MeasureTime frameDescription
The number of patients with complete miscarriage at 1 week7 daysThe number of patients with complete miscarriage at 1 week

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026